REG - IXICO plc - Contract Win

IXICOAnnouncement

14/06/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230614:nRSN5944Ca&default-theme=true

RNS Number : 5944C  IXICO plc  14 June 2023

14 June 2023

IXICO plc

 

("IXICO", the "Company" or the "Group")

 

Contract win in Huntington's disease worth circa £2M

 

IXICO plc (AIM: IXI), the medical imaging advanced analytics company
delivering intelligent insights in neuroscience, is pleased to announce that
an existing client has contracted IXICO to provide imaging services for the
extension study of their Huntington's disease ('HD') Ph2b trial. This is a new
study protocol and results in a new work order worth just under £2M which
IXICO expects to deliver over the next 4 years.

 

HD is a rare, inherited disease that causes the progressive breakdown of nerve
cells in the brain affecting movement, mood and thinking abilities.

 

Giulio Cerroni, CEO of IXICO, commented: "We are delighted to be awarded this
contract to support the ongoing development programme of this promising
treatment in HD.  This contract strengthens our order book, securing further
visibility to future anticipated revenues. We have been working with this
client for several years and I am delighted to be further deepening our
long-term partnership as they pursue a treatment for this terrible
neurological disease."

 

 

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulation
(EU) No. 596/2014 as amended by The Market Abuse (Amendment) (EU Exit)
Regulations 2019. Upon the publication of this announcement via the Regulatory
Information Service, this inside information is now considered to be in the
public domain.

 

For further information please contact:

 

 IXICO plc                                         +44 (0)20 3763 7499

 Giulio Cerroni, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cenkos Securities PLC (Nominated adviser and sole broker)                         +44 (0)20 7397 8900

 Giles Balleny / Max Gould (Corporate Finance)
 Michael F Johnson / Tamar Cranford-Smith (Sales)

 

About IXICO

 

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's disease, Parkinson's disease and Alzheimer's disease. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough data analytics, at scale,
through its remote access technology platform, to improve the return on
investment in drug development and reduce risk and uncertainty in clinical
trials for the Company's pharmaceutical clients.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  CNTUOOSROVUNAAR